Welcome to the eilslabs

The eilslabs form a joint research group between the division "Theoretical Bioinformatics" at the German Cancer Research Center (dkfz) and the department Bioinformatics and Functional Genomics at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University. The group is headed by Prof. Roland Eils.

 


 

Chromsomen-alleine

In a recent research highlight in Genome Medicine (1), Matthias Schlesner and Roland Eils discuss the impact of genome hypermutation on the development of certain cancers. A recent study by Shlien et al. (2) describes that tumors from children with congenital biallelic mismatch repair deficiency (bMMRD) show an extremely high mutation rate (named "ultra-hypermutation”), exceeding even highly mutated adult cancers by one order of magnitude. Together with other studies on genome hypermutation in cancer, e.g. the earlier work of the eilslabs on X-Chromosome hypermutation (3), these findings might lead to the development of new therapeutic approaches to combat cancer.

Citations:

  1. (1) Schlesner, M., & Eils, R. (2015). Hypermutation takes the driver's seat. Genome Med, 7(1), 31. doi: 10.1186/s13073-015-0159-x
  2. (2) Shlien, A., Campbell, B. B., de Borja, R., Alexandrov, L. B., Merico, D., Wedge, D., . . . Biallelic Mismatch Repair Deficiency, C. (2015). Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet, 47(3), 257-262. doi: 10.1038/ng.3202
  3. (3) Jäger, N., Schlesner, M., Jones, David T. W., Raffel, S., Mallm, J.-P., Junge, Kristin M., . . . Eils, R. (2013). Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer. CELL, 155(3), 567-581. doi: 10.1016/j.cell.2013.09.042
Matthias Schlesner and Roland Eils discuss new findings regarding the effect of genome hypermutation in cancerthe impact of genome hypermutation on the development of certain cancers. They describe a newA recent study by Shlien et al.